Promising Alzheimer's treatment flops in new trial

The US reports

"...In TauRx’s trial there are an exciting sub-set of patients that were at an early stage in their disease (mild to moderate) that responded exceedingly well to LMTX as a drug on its own (monotherapy) showing all the signs of a slowing in disease progression, with improvements in cognitive function and the brains’ appearance when scanned .

However, these patients were only about 15% of the total number of patients treated so far and so not enough to draw any firm conclusions. We now have to wait for the results of TauRx’s second Phase III trial which is expected later this year and is focussing on monotherapy of 800 patients with mild disease, he said..."

Look back at pharma news to July 29